Chemoradioimmunotherapy versus chemoimmunotherapy or chemoradiotherapy in extensive‐stage small‐cell lung cancer: A retrospective analysis of survival outcomes

Jinmin Han, Ying Hua, Xue Wu, Xiufeng Tang, Chengxin Liu · 2025

Read Chemoradioimmunotherapy versus chemoimmunotherapy or chemoradiotherapy in extensive‐stage small‐cell lung cancer: A retrospective analysis of survival outcomes by Jinmin Han, Ying Hua, Xue Wu, Xiufeng Tang, Chengxin Liu (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12750307.txt.

Description

Jinmin Han and four co-authors weigh, in 2025 records work, three care blends for wide-spread small-cell lung cancer. Whether chest rays add worth atop drug-plus-guard care was unsettled. Two hundred six patients split into guard-based care and drug-plus-ray care, the first split again by whether rays joined.

The full three-way blend lived longest at the mid mark, past drug-plus-guard alone; drug-plus-ray alone sat in the mid. Tumour shrink rates ran near alike across arms, a touch ahead in the full blend. No gap hit the firm bar. The team backs chest rays as fit in the guard era, and plain drug-plus-ray where means are thin.

Catalog record

CREATORJinmin Han, Ying Hua, Xue Wu, Xiufeng Tang, Chengxin Liu
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE26 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12750307

Browse the full library · About the Tower of Babel